ASKA Pharmaceutical Holdings aims to become a total healthcare company with a strong foundation as a specialty pharma company through its pharmaceutical business, animal health business, and hormone testing business, based on ASKA’s DNA, the source of its growth for over 100 years.
Through this value creation cycle, we will contribute to the resolution of social issues in the field of healthcare.
* Click on the image for a larger view. [PDF]
ASKA Pharmaceutical Holdings has correctly analyzed the "current situation" and the associated "opportunities" and "risks" for the sustainable growth of each group company, and has identified 11 "materialities" as the most important issues to be addressed from the perspective of relevance to our business and contribution to society.
In particular, the entire group will work on each item based on "contribution to women's health" and "contribution to animal health," which are materialities in which we can demonstrate our strengths.
Our business model will continue the cycle from prevention to examination/diagnosis, treatment, and prognosis, based on three main businesses: ethical pharmaceuticals, animal health, and testing.
We are working to achieve a consolidated economic value target of 70 billion yen in sales, operating margin of 8%, and ROE of 8% in FY2025.
Based on the social value of providing high-quality pharmaceutical products, promoting drug discovery through open innovation, and providing new initiatives and value toward total healthcare, we are working to become a total healthcare company based on specialty pharmaceuticals.